Provided by Tiger Trade Technology Pte. Ltd.

Emergent BioSolutions

8.11
-0.1025-1.25%
Volume:139.35K
Turnover:1.15M
Market Cap:419.73M
PE:8.72
High:8.43
Open:8.23
Low:8.10
Close:8.21
52wk High:14.06
52wk Low:4.02
Shares:51.77M
Float Shares:51.26M
Volume Ratio:0.53
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9300
EPS(LYR):0.9300
ROE:10.46%
ROA:5.34%
PB:0.80
PE(LYR):8.72

Loading ...

BRIEF-Emergent Bio- Receives $21.5 Mln Order From U.S. Department Of War To Supply Biothrax In 2026

Reuters
·
Jan 09

Emergent BioSolutions Inc - Receives $21.5 Mln Order From U.S. Department of War to Supply Biothrax in 2026

THOMSON REUTERS
·
Jan 09

Emergent BioSolutions Receives $21.5 Million Order to Supply Anthrax Vaccine to U.S. Department of War

Reuters
·
Jan 09

Emergent BioSolutions: Strategic Infectious Disease Positioning and Countermeasure Demand Support Buy Rating and $15 Target

TIPRANKS
·
Jan 08

Emergent BioSolutions Partners with PANTHER to Support Africa CDC-Led Mpox Study

Reuters
·
Jan 08

Emergent BioSolutions and Panther Announce Agreement to Support the Continuation of the Africa Cdc-Led Mpox Study in Africa

THOMSON REUTERS
·
Jan 08

Emergent BioSolutions Inc - Africa Cdc and Panther to Extend Study to Uganda

THOMSON REUTERS
·
Jan 08

Emergent Biosolutions Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 16, 2025

FDA Approves Emergent BioSolutions Winnipeg Facility for Raxibacumab Manufacturing

Reuters
·
Dec 12, 2025

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of Raxibacumab at Its Winnipeg, Canada Site

THOMSON REUTERS
·
Dec 12, 2025

Director Ronald Richard Sells Common Shares of Emergent BioSolutions Inc

Reuters
·
Dec 10, 2025

BUZZ-Bavarian Nordic rises on share buyback - 'positive signal' for investors

Reuters
·
Dec 02, 2025

Bid-Ask Spreads on Currencies Narrow as EBS Trade Resumes -- Market Talk

Dow Jones
·
Nov 28, 2025

BRIEF-Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access

Reuters
·
Nov 18, 2025

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of Narcan® Nasal Spray and Reinforces Its Commitment to Increasing Naloxone Access

THOMSON REUTERS
·
Nov 18, 2025

Aptevo Therapeutics Director Grady Grant III Acquires Common Shares

Reuters
·
Nov 13, 2025

Emergent BioSolutions Announces Retirement of DR. Louis W. Sullivan From Board of Directors

THOMSON REUTERS
·
Nov 13, 2025

Press Release: Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Dow Jones
·
Nov 13, 2025

Director Sujata Tyagi Dayal Sells Common Shares of Emergent BioSolutions Inc

Reuters
·
Nov 11, 2025

Aptevo Therapeutics Unveils Preclinical Data for Trispecific Antibody APVO451 in Solid Tumors

Reuters
·
Nov 10, 2025